Benzinga | Jul 30, 2021 09:32AM EDT

I-Mab To Start Testing Alzheimer's Candidate In Human Trials

* The FDA has signed off I-Mab (NASDAQ:IMAB) Investigational New Drug (IND) application for Protollin, an Alzheimer's candidate.

* Brigham and Women's Hospital and Inspirevax granted I-Mab and Nhwa global exclusive licenses to develop, manufacture, and commercialize Protollin.

* Inspirevax will manufacture and supply Protollin for preclinical and clinical studies until the recruitment of the first patient in the Phase 1b MAD study.

* I-Mab will develop and commercialize Protollin outside of the Greater China territory, while Nhwa will develop and commercialize the drug in mainland China, Hong Kong, Macau, and Taiwan.

* Price Action: IMAB shares are down 1.51% at $73.45 during the market session on the last check Friday.

* Related content: Benzinga's Full FDA Calendar.